Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mino-Lok Phase 3 for CRBSI/CLABSI
NCT02901717Phase 3Unknown
- Sponsor
- Leonard-Meron Biosciences, Inc.
- Start
- Feb 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of minocycline + edta + ethanol in catheter-related bloodstream infection (CRBSI) (2 arms), sponsored by Leonard-Meron Biosciences, Inc. Primary endpoint: Time to a catheter failure event at 6 weeks. Status: unknown.
02
Drugs
minocycline + edta + ethanol
03
Conditions
catheter-related bloodstream infection (CRBSI)
Beyond the preview
Go deeper on NCT02901717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901717.